+1.650.627.4531 inquiry@medeortx.com
Contact Us| Find us on:

News

Medeor Therapeutics Expands Executive Team

SAN MATEO, Calif.April 4, 2018 — Medeor Therapeutics, Inc., a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of personalized cellular immunotherapies, today announced the appointment of Iqbal Husain, Ph.D., as its Senior Vice President, Program Management, and Michael Zdanowski as its Vice President, Biopharmaceutical Operations.

Open Press Release >>


Medeor Therapeutics to Present at Cowen Health Care Conference

SAN MATEO, Calif.March 8, 2018 — Medeor Therapeutics, Inc., a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of personalized cellular immunotherapies, today announced that its President and Chief Executive Officer, Dr. Steven R. Deitcher, will present on Wednesday, March 14that 1:00 p.m. EST at the Cowen and Company 38th annual Health Care Conference in Boston.

Open Press Release >>


Medeor Therapeutics Awarded $18.8 Million From the California Institute for Regenerative Medicine

SAN MATEO, Calif.Jan. 22, 2018 — Medeor Therapeutics, Inc., a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of personalized cellular immunotherapies, today announced that the California Institute for Regenerative Medicine (CIRM) has approved an award to the company for $18.8 million under its Clinical Trial Funding Initiative. The award is to support a Phase 3 clinical trial to evaluate the safety and efficacy of MDR-101, the company’s development-stage donor-specific cell therapy program for HLA-matched living donor kidney transplant patients.

Open Press Release >>


Medeor Therapeutics Raises $57 Million In Series B Financing

SAN MATEO, Calif.Nov. 27, 2017 — Medeor Therapeutics, Inc., a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of personalized cellular immunotherapies, today announced that it has closed an oversubscribed $57 million Series B financing, led by RA Capital Management. Additional new investors included Sofinnova Ventures and 6 Dimensions Capital, who were joined by existing investors Vivo Capital and WuXi Healthcare Ventures. In conjunction with the financing, Peter Kolchinsky, Ph.D., Portfolio Manager and Managing Director at RA Capital, and Anand Mehra, M.D., General Partner at Sofinnova Ventures, have joined the company’s Board of Directors.

Open Press Release >>